Topical nonsteroidal anti-inflammatory drugs for macular edema

Andrea Russo, Ciro Costagliola, Luisa Delcassi, Francesco Parmeggiani, Mario R Romano, Roberto Dell'Omo, Francesco Semeraro, Andrea Russo, Ciro Costagliola, Luisa Delcassi, Francesco Parmeggiani, Mario R Romano, Roberto Dell'Omo, Francesco Semeraro

Abstract

Nonsteroidal anti-inflammatory drugs (NSAIDs) are nowadays widely used in ophthalmology to reduce eye inflammation, pain, and cystoid macular edema associated with cataract surgery. Recently, new topical NSAIDs have been approved for topical ophthalmic use, allowing for greater drug penetration into the vitreous. Hence, new therapeutic effects can be achieved, such as reduction of exudation secondary to age-related macular degeneration or diabetic maculopathy. We provide an updated review on the clinical use of NSAIDs for retinal diseases, with a focus on the potential future applications.

References

    1. Schoenberger SD, Kim SJ. Nonsteroidal anti-inflammatory drugs for retinal disease. International Journal of Inflammation. 2013;2013:8 pages.281981
    1. Flach AJ. Cyclo-oxygenase inhibitors in ophthalmology. Survey of Ophthalmology. 1992;36(4):259–284.
    1. Flach AJ. Topical nonsteroidal antiinflammatory drugs in ophthalmology. International Ophthalmology Clinics. 2002;42(1):1–11.
    1. Flaxel C, Schain MB, Hamon SC, Francis PJ. Prospective randomized controlled trial of combination ranibizumab (lucentis) and bromfenac (xibrom) for neovascular age-related macular degeneration: a pilot study. Retina. 2012;32(3):417–423.
    1. Gomi F, Sawa M, Tsujikawa M, Nishida K. Topical bromfenac as an adjunctive treatment with intravitreal ranibizumab for exudative age-related macular degeneration. Retina. 2012;32:1804–1810.
    1. Filho JPS, Martins MC, Correa ZMS, et al. The expression of cyclooxygenase 2 in retinoblastoma: primary enucleated eyes and enucleation after conservative treatment. American Journal of Ophthalmology. 2006;142(4):625–631.
    1. Russo A, Costagliola C, Delcassi L, Romano MR, Semeraro F. A randomised controlled trial of ranibizumab with and without ketorolac eyedrops for exudative age-related macular degeneration. British Journal of Ophthalmology. 2013;97(10):1273–1276.
    1. Takahashi H, Yanagi Y, Tamaki Y, Uchida S, Muranaka K. COX-2-selective inhibitor, etodolac, suppresses choroidal neovascularization in a mice model. Biochemical and Biophysical Research Communications. 2004;325(2):461–466.
    1. Ahuja M, Dhake AS, Sharma SK, Majumdar DK. Topical ocular delivery of NSAIDs. AAPS Journal. 2008;10(2):229–241.
    1. Miyake K, Ibaraki N. Prostaglandins and cystoid macular edema. Survey of Ophthalmology. 2002;47(supplement 1):S203–S218.
    1. Simmons DL, Botting RM, Hla T. Cyclooxygenase isozymes: the biology of prostaglandin synthesis and inhibition. Pharmacological Reviews. 2004;56(3):387–437.
    1. Davies NM, Good RL, Roupe KA, Yáñez JA. Cyclooxygenase-3: axiom, dogma, anomaly, enigma or splice error?—Not as easy as 1, 2, 3. Journal of Pharmacy & Pharmaceutical Sciences. 2004;7:217–226.
    1. Botting RM. Vane’s discovery of the mechanism of action of aspirin changed our understanding of its clinical pharmacology. Pharmacological Reports. 2010;62(3):518–525.
    1. Chin MS, Nagineni CN, Hooper LC, Detrick B, Hooks JJ. Cyclooxygenase-2 gene expression and regulation in human retinal pigment epithelial cells. Investigative Ophthalmology and Visual Science. 2001;42(10):2338–2346.
    1. Needleman P, Isakson PC. The discovery and function of COX-2. Journal of Rheumatology. 1997;24(49):6–8.
    1. Kim SJ, Flach AJ, Jampol LM. Nonsteroidal anti-inflammatory drugs in ophthalmology. Survey of Ophthalmology. 2010;55(2):108–133.
    1. Kim SJ, Toma HS, Barnett JM, Penn JS. Ketorolac inhibits choroidal neovascularization by suppression of retinal VEGF. Experimental Eye Research. 2010;91(4):537–543.
    1. Kim SJ, Toma HS. Inhibition of choroidal neovascularization by intravitreal ketorolac. Archives of Ophthalmology. 2010;128(5):596–600.
    1. Maloney SC, Fernandes BF, Castiglione E, et al. Expression of cyclooxygenase-2 in choroidal neovascular membranes from age-related macular degeneration patients. Retina. 2009;29(2):176–180.
    1. Aiello LP, Pierce EA, Foley ED, et al. Suppression of retinal neovascularization in vivo by inhibition of vascular endothelial growth factor (VEGF) using soluble VEGF-receptor chimeric proteins. Proceedings of the National Academy of Sciences of the United States of America. 1995;92(23):10457–10461.
    1. Ayalasomayajula SP, Kompella UB. Celecoxib, a selective cyclooxygenase-2 inhibitor, inhibits retinal vascular endothelial growth factor expression and vascular leakage in a streptozotocin-induced diabetic rat model. European Journal of Pharmacology. 2003;458(3):283–289.
    1. Johnson EIM, Dunlop ME, Larkins RG. Increased vasodilatory prostaglandin production in the diabetic rat retinal vasculature. Current Eye Research. 1999;18(2):79–82.
    1. Deutsch TA, Hughes WF. Suppressive effects of indomethacin on thermally induced neovascularization of rabbit corneas. American Journal of Ophthalmology. 1979;87(4):536–540.
    1. Monnier Y, Zaric J, Rüegg C. Inhibition of angiogenesis by non-steroidal anti-inflammatory drugs: from the bench to the bedside and back. Current Drug Targets. 2005;4(1):31–38.
    1. Sawaoka H, Tsuji S, Tsujii M, et al. Cyclooxygenase inhibitors suppress angiogenesis and reduce tumor growth in vivo. Laboratory Investigation. 1999;79(12):1469–1477.
    1. Yamada M, Kawai M, Kawai Y, Mashima Y. The effect of selective cyclooxygenase-2 inhibitor on corneal angiogenesis in the rat. Current Eye Research. 1999;19(4):300–304.
    1. Joussen AM, Poulaki V, Mitsiades N, et al. Nonsteroidal anti-inflammatory drugs prevent early diabetic retinopathy via TNF-alpha suppression. The FASEB Journal. 2002;16(3):438–440.
    1. Kern TS, Miller CM, Du Y, et al. Topical administration of nepafenac inhibits diabetes-induced retinal microvascular disease and underlying abnormalities of retinal metabolism and physiology. Diabetes. 2007;56(2):373–379.
    1. Tasman W, Jaeger EA. Duane’s Foundations of Clinical Ophthalmology: Ocular Anatomy, Embryology and Teratology. Physiology of the Eye and Visual System. Pathology of the Eye. Philadelphia, Pa, USA: J.B. Lippincott; 1991.
    1. Schalnus R. Topical nonsteroidal anti-inflammatory therapy in ophthalmology. Ophthalmologica. 2003;217(2):89–98.
    1. Gupta M, Majumdar DK. Effect of concentration, pH, and preservative on in vitro transcorneal permeation of ibuprofen and flurbiprofen from non-buffered aqueous drops. Indian Journal of Experimental Biology. 1997;35(8):844–849.
    1. Chen E, Benz MS, Fish RH, et al. Use of nepafenac (Nevanac)in combination with intravitreal anti-VEGF agents in the treatment of recalcitrant exudative macular degeneration requiring monthly injections. Clinical Ophthalmology. 2010;4(1):1249–1252.
    1. Zweifel SA, Engelbert M, Khan S, Freund KB. Retrospective review of the efficacy of topical bromfenac (0.09%) as an adjunctive therapy for patients with neovascular age-related macular degeneration. Retina. 2009;29(10):1527–1531.
    1. Ke T, Graff G, Spellman JM, Yanni JM. Nepafenac, a unique nonsteroidal prodrug with potential utility in the treatment of trauma-induced ocular inflammation: II. In vitro bioactivation and permeation of external ocular barriers. Inflammation. 2000;24(4):371–384.
    1. Walters T, Raizman M, Ernest P, Gayton J, Lehmann R. In vivo pharmacokinetics and in vitro pharmacodynamics of nepafenac, amfenac, ketorolac, and bromfenac. Journal of Cataract and Refractive Surgery. 2007;33(9):1539–1545.
    1. Gamache DA, Graff G, Brady MT, Spellman JM, Yanni JM. Nepafenac, a unique nonsteroidal prodrug with potential utility in the treatment of trauma-induced ocular inflammation: i. Assessment of anti- inflammatory efficacy. Inflammation. 2000;24(4):357–370.
    1. Bucci FA, Waterbury LD. Prostaglandin E2 inhibition of ketorolac 0.45%, bromfenac 0.09%, and nepafenac 0.1% in patients undergoing phacoemulsification. Advances in therapy. 2011;28(12):1089–1095.
    1. Bucci FA, Jr., Waterbury LD. A randomized comparison of to-aqueous penetration of ketorolac 0.45%, bromfenac 0.09% and nepafenac 0.1% in cataract patients undergoing phacoemulsification. Current Medical Research and Opinion. 2011;27(12):2235–2239.
    1. Waterbury LD, Silliman D, Jolas T. Comparison of cyclooxygenase inhibitory activity and ocular anti-inflammatory effects of ketorolac tromethamine and bromfenac sodium. Current Medical Research and Opinion. 2006;22(6):1133–1140.
    1. Ellis PP, Pfoff DS, Bloedow DC, Riegel M. Intraocular diclofenac and flurbiprofen concentrations in human aqueous humor following topical application. Journal of Ocular Pharmacology. 1994;10(4):677–682.
    1. Bucci FA, Jr., Waterbury LD, Amico LM. Prostaglandin E2 inhibition and aqueous concentration of ketorolac 0.4% (acular LS) and nepafenac 0.1% (nevanac) in patients undergoing phacoemulsification. American Journal of Ophthalmology. 2007;144(1):146–147.
    1. Heier JS, Awh CC, Busbee BG, et al. Vitreous nonsteroidal antiinflammatory drug concentrations and prostaglandin E2 levels in vitrectomy patients treated with ketorolac 0.4%, bromfenac 0.09%, and nepafenac 0.1% Retina. 2009;29(9):1310–1313.
    1. Quaranta L, Katsanos A, Russo A, Riva I. 24-hour intraocular pressure and ocular perfusion pressure in glaucoma. Survey of Ophthalmology. 2013;58:26–41.
    1. Costagliola C, Parmeggiani F, Antinozzi PP, Caccavale A, Cotticelli L, Sebastiani A. The influence of diclofenac ophthalmic solution on the intraocular pressure-lowering effect of topical 0.5% timolol and 0.005% latanoprost in primary open-angle glaucoma patients. Experimental Eye Research. 2005;81(5):610–615.
    1. Costagliola C, Campa C, Perri P, Parmeggiani F, Romano MR, Incorvaia C. Topical and oral ketorolac administration increases the intraocular pressure-lowering effect of latanoprost. Current Eye Research. 2008;33(5-6):477–482.
    1. Flach AJ. Topical nonsteroidal antiinflammatory drugs in ophthalmology. International Ophthalmology Clinics. 2002;42(1):1–11.
    1. Gallenga PE, Mastropasqua L, Lobefalo L, et al. Efficacy of diclofenac eyedrops in preventing postoperative inflammation and long-term cystoid macular edema. Journal of Cataract and Refractive Surgery. 1997;23(8):1183–1189.
    1. Blaydes JE, Jr., Kelley EP, Walt JG, DeGryse RE, Harper DG, Novack GD. Flurbiprofen 0.03% for the control of inflammation following cataract extraction by phacoemulsification. Journal of Cataract and Refractive Surgery. 1993;19(4):481–487.
    1. Donnenfeld ED, Holland EJ, Stewart RH, Gow JA, Grillone LR. Bromfenac ophthalmic solution 0.09% (Xibrom) for postoperative ocular pain and inflammation. Ophthalmology. 2007;114(9):1653–1662.
    1. Heier J, Cheetham JK, DeGryse R, et al. Ketorolac tromethamine 0.5% ophthalmic solution in the treatment of moderate to severe ocular inflammation after cataract surgery: a randomized, vehicle-controlled clinical trial. American Journal of Ophthalmology. 1999;127(3):253–259.
    1. Duong HQ, Westfield KC, Chalkley THF. Ketorolac tromethamine LS 0.4% versus nepafenac 0.1% in patients having cataract surgery. Prospective randomized double-masked clinical trial. Journal of Cataract and Refractive Surgery. 2007;33(11):1925–1929.
    1. Hirneiss C, Neubauer AS, Kampik A, Schönfeld C. Comparison of prednisolone 1%, rimexolone 1% and ketorolac tromethamine 0.5% after cataract extraction. A prospective, randomized, double-masked study. Graefe’s Archive for Clinical and Experimental Ophthalmology. 2005;243(8):768–773.
    1. Kraff MC, Martin RG, Neumann AC, Weinstein AJ. Efficacy of diclofenac sodium ophthalmic solution versus placebo in reducing inflammation following cataract extraction and posterior chamber lens implantation. Journal of Cataract and Refractive Surgery. 1994;20(2):138–144.
    1. Lane SS, Modi SS, Lehmann RP, Holland EJ. Nepafenac ophthalmic suspension 0.1% for the prevention and treatment of ocular inflammation associated with cataract surgery. Journal of Cataract and Refractive Surgery. 2007;33(1):53–58.
    1. Missotten L, Richard C, Trinquand C, et al. Topical 0.1% indomethacin solution versus topical 0.1% dexamethasone solution in the prevention of inflammation after cataract surgery. Ophthalmologica. 2001;215(1):43–50.
    1. Simone JN, Pendelton RA, Jenkins JE. Comparison of the efficacy and safety of ketorolac tromethamine 0.5% and prednisolone acetate 1% after cataract surgery. Journal of Cataract and Refractive Surgery. 1999;25(5):699–704.
    1. Solomon KD, Cheetham JK, DeGryse R, Brint SF, Rosenthal A. Topical ketorolac tromethamine 0.5% ophthalmic solution in ocular inflammation after cataract surgery. Ophthalmology. 2001;108(2):331–337.
    1. Wittpenn JR, Silverstein S, Heier J, Kenyon KR, Hunkeler JD, Earl M. A randomized, masked comparison of topical ketorolac 0. 4% plus steroid vs steroid alone in low-risk cataract surgery patients. American Journal of Ophthalmology. 2008;146(4):554–560.
    1. Flach AJ, Kraff MC, Sanders DR, Tanenbaum L. The quantitative effect of 0.5% ketorolac tromethamine solution and 0.1% dexamethasone sodium phosphate solution on postsurgical blood-aqueous barrier. Archives of Ophthalmology. 1988;106(4):480–483.
    1. Heier JS, Topping TM, Baumann W, Dirks MS, Chern S. Ketorolac versus prednisolone versus combination therapy in the treatment of acute pseudophakic cystoid macular edema. Ophthalmology. 2000;107(11):2034–2039.
    1. Kim SJ, Lo WR, Hubbard GB, III, et al. Topical ketorolac in vitreoretinal surgery: a prospective, randomized, placebo-controlled, double-masked trial. Archives of Ophthalmology. 2008;126(9):1203–1208.
    1. Loewenstein A, Zur D. Postsurgical cystoid macular edema. Developments in Ophthalmology. 2010;47:148–159.
    1. Flach AJ. The incidence, pathogenesis and treatment of cystoid macular edema following cataract surgery. Transactions of the American Ophthalmological Society. 1998;96:557–634.
    1. Yilmaz T, Cordero-Coma M, Gallagher MJ. Ketorolac therapy for the prevention of acute pseudophakic cystoid macular edema: a systematic review. Eye. 2012;26(2):252–258.
    1. Ersoy L, Caramoy A, Ristau T, Kirchhof B, Fauser S. Aqueous flare is increased in patients with clinically significant cystoid macular oedema after cataract surgery. British Journal of Ophthalmology. 2013;97:862–865.
    1. Kim SJ, Equi R, Bressler NM. Analysis of macular edema after cataract surgery in patients with diabetes using optical coherence tomography. Ophthalmology. 2007;114(5):881–889.
    1. Lobo CL, Faria PM, Soares MA, Bernardes RC, Cunha-Vaz JG. Macular alterations after small-incision cataract surgery. Journal of Cataract and Refractive Surgery. 2004;30(4):752–760.
    1. Ursell PG, Spalton DJ, Whitcup SM, Nussenblatt RB. Cystoid macular edema after phacoemulsification: relationship to blood-aqueous barrier damage and visual acuity. Journal of Cataract and Refractive Surgery. 1999;25(11):1492–1497.
    1. Rossetti L, Chaudhuri J, Dickersin K. Medical prophylaxis and treatment of cystoid macular edema after cataract surgery: the results of a meta-analysis. Ophthalmology. 1998;105(3):397–405.
    1. Miyake K, Sakamura S, Miura H. Long-term follow-up study on prevention of aphakic cystoid macular oedema by topical indomethacin. British Journal of Ophthalmology. 1980;64(5):324–328.
    1. Yannuzzi LA, Landau AN, Turtz AI. Incidence of aphakic cystoid macular edema with the use of topical indomethacin. Ophthalmology. 1981;88(9):947–954.
    1. Kraff MC, Sanders DR, Jampol LM. Prophylaxis of pseudophakic cystoid macular edema with topical indomethacin. Ophthalmology. 1982;89(8):885–890.
    1. Flach AJ, Stegman RC, Graham J, Kruger LP. Prophylaxis of aphakic cystoid macular edema without corticosteroids: a paired-comparison, placebo-controlled double-masked study. Ophthalmology. 1990;97(10):1253–1258.
    1. Solomon LD, Boyaner D, Breslin CW, et al. Efficacy of topical flurbiprofen and indomethacin in preventing pseudophakic cystoid macular edema. Journal of Cataract and Refractive Surgery. 1995;21(1):73–81.
    1. Miyake K, Masuda K, Shirato S, et al. Comparison of diclofenac and fluorometholone in preventing cystoid macular edema after small incision cataract surgery: a multicentered prospective trial. Japanese Journal of Ophthalmology. 2000;44(1):58–67.
    1. Kim SJ, Bressler NM. Optical coherence tomography and cataract surgery. Current Opinion in Ophthalmology. 2009;20(1):46–51.
    1. Yannuzzi LA, Klein RM, Wallyn RH. Ineffectiveness of indomethacin in the treatment of chronic cystoid macular edema. American Journal of Ophthalmology. 1977;84(4):517–519.
    1. Burnett J, Tessler H, Isenberg S, Tso MOM. Double-masked trial of fenoprofen sodium: treatment of chronic aphakic cystoid macular edema. Ophthalmic Surgery. 1983;14(2):150–152.
    1. Flach AJ, Dolan BJ, Irvine AR. Effectiveness of ketorolac tromethamine 0.5% ophthalmic solution for chronic aphakic and pseudophakic cystoid macular edema. American Journal of Ophthalmology. 1987;103(4):479–486.
    1. Flach AJ, Jampol LM, Weinberg D, et al. Improvement in visual acuity in chronic aphakic and pseudophakic cystoid macular edema after treatment with topical 0.5% ketorolac tromethamine. American Journal of Ophthalmology. 1991;112(5):514–519.
    1. Sivaprasad S, Bunce C, Crosby-Nwaobi R. Non-steroidal anti-inflammatory agents for treating cystoid macular oedema following cataract surgery. In: Sivaprasad S, editor. The Cochrane Collaboration. Chichester, UK: John Wiley & Sons; 2012. (Cochrane Database of Systematic Reviews).
    1. Almeida DRP, Khan Z, Xing L, et al. Prophylactic nepafenac and ketorolac versus placebo in preventing postoperative macular edema after uneventful phacoemulsification. Journal of Cataract & Refractive Surgery. 2012;38:1537–1543.
    1. Warren KA, Bahrani H, Fox JE. NSAIDs in combination therapy for the treatment of chronic pseudophakic cystoid macular edema. Retina. 2010;30(2):260–266.
    1. Hariprasad SM, Akduman L, Clever JA, Ober M, Recchia FM, Mieler WF. Treatment of cystoid macular edema with the new-generation NSAID nepafenac 0.1% Clinical Ophthalmology. 2009;3(1):147–154.
    1. Klein R, Peto T, Bird A, Vannewkirk MR. The epidemiology of age-related macular degeneration. American Journal of Ophthalmology. 2004;137(3):486–495.
    1. D'Amico DJ. Diseases of the retina. The New England Journal of Medicine. 1994;331:95–106.
    1. Rosenfeld PJ, Brown DM, Heier JS, et al. Ranibizumab for neovascular age-related macular degeneration. The New England Journal of Medicine. 2006;355(14):1419–1431.
    1. Brown DM, Kaiser PK, Michels M, et al. Ranibizumab versus verteporfin for neovascular age-related macular degeneration. The New England Journal of Medicine. 2006;355(14):1432–1444.
    1. Zarbin MA. Current concepts in the pathogenesis of age-related macular degeneration. Archives of Ophthalmology. 2004;122(4):598–614.
    1. Edwards AO, Ritter R, III, Abel KJ, Manning A, Panhuysen C, Farrer LA. Complement factor H polymorphism and age-related macular degeneration. Science. 2005;308(5720):421–424.
    1. Haines JL, Hauser MA, Schmidt S, et al. Complement factor H variant increases the risk of age-related macular degeneration. Science. 2005;308(5720):419–421.
    1. Klein RJ, Zeiss C, Chew EY, et al. Complement factor H polymorphism in age-related macular degeneration. Science. 2005;308(5720):385–389.
    1. Thakkinstian A, Han P, McEvoy M, et al. Systematic review and meta-analysis of the association between complementary factor H Y402H polymorphisms and age-related macular degeneration. Human Molecular Genetics. 2006;15(18):2784–2790.
    1. Parmeggiani F, Romano MR, Costagliola C, et al. Mechanism of inflammation in age-related macular degeneration. Mediators of Inflammation. 2012;2012:16 pages.546786
    1. Bora PS, Sohn J, Cruz JMC, et al. Role of complement and complement membrane attack complex in laser-induced choroidal neovascularization. Journal of Immunology. 2005;174(1):491–497.
    1. Patel M, Chan C. Immunopathological aspects of age-related macular degeneration. Seminars in Immunopathology. 2008;30(2):97–110.
    1. Wang Y, Wang VM, Chan C-C. The role of anti-inflammatory agents in age-related macular degeneration (AMD) treatment. Eye. 2011;25(2):127–139.
    1. Penfold PL, Provis JM, Furby JH, Gatenby PA, Billson FA. Autoantibodies to retinal astrocytes associated with age-related macular degeneration. Graefe's Archive for Clinical and Experimental Ophthalmology. 1990;228:270–274.
    1. Gu X, Meer SG, Miyagi M, et al. Carboxyethylpyrrole protein adducts and autoantibodies, biomarkers for age-related macular degeneration. The Journal of Biological Chemistry. 2003;278(43):42027–42035.
    1. Morohoshi K, Goodwin AM, Ohbayashi M, Ono SJ. Autoimmunity in retinal degeneration: autoimmune retinopathy and age-related macular degeneration. Journal of Autoimmunity. 2009;33(3-4):247–254.
    1. in ’t Veld BA, Ruitenberg A, Hofman A, et al. Nonsteroidal antiinflammatory drugs and the risk of Alzheimer’s disease. The New England Journal of Medicine. 2001;345(21):1515–1521.
    1. Stewart WF, Kawas C, Corrada M, Metter EJ. Risk of Alzheimer’s disease and duration of NSAID use. Neurology. 1997;48(3):626–632.
    1. McGeer PL, Sibley J. Sparing of age-related macular degeneration in rheumatoid arthritis. Neurobiology of Aging. 2005;26(8):1199–1203.
    1. Wilson HL, Schwartz DM, Bhatt HRF, McCulloch CE, Duncan JL. Statin and aspirin therapy are associated with decreased rates of choroidal neovascularization among patients with age-related macular degeneration. American Journal of Ophthalmology. 2004;137(4):615–624.
    1. Suzuki M, Suzuki T, Nagano A, Hirasawa M, Sakuyama K, Mizuki N. Cyclooxygenase inhibitor improved an exudative lesion of choroidal neovascularization in age-related macular degeneration. European Journal of Ophthalmology. 2012;22:495–498.
    1. Liew G, Mitchell P, Wong TY, Rochtchina E, Wang JJ. The association of aspirin use with age-related macular degeneration. JAMA Internal Medicine. 2013;173:258–264.
    1. de Jong PTVM, Chakravarthy U, Rahu M, et al. Associations between aspirin use and aging macula disorder: the European eye study. Ophthalmology. 2012;119(1):112–118.
    1. Du Y, Sarthy VP, Kern TS. Interaction between NO and COX pathways in retinal cells exposed to elevated glucose and retina of diabetic rats. American Journal of Physiology—Regulatory Integrative and Comparative Physiology. 2004;287(4):R735–R741.
    1. Yanni SE, McCollum GW, Penn JS. Genetic deletion of COX-2 diminishes VEGF production in mouse retinal Müller cells. Experimental Eye Research. 2010;91(1):34–41.
    1. Antonetti DA, Klein R, Gardner TW. Diabetic retinopathy. The New England Journal of Medicine. 2012;366(13):1227–1239.
    1. Knudsen ST, Bek T, Poulsen PL, Hove MN, Rehling M, Mogensen CE. Macular edema reflects generalized vascular hyperpermeability in type 2 diabetic patients with retinopathy. Diabetes Care. 2002;25(12):2328–2334.
    1. Funatsu H, Yamashita H, Ikeda T, Nakanishi Y, Kitano S, Hori S. Angiotensin II and vascular endothelial growth factor in the vitreous fluid of patients with diabetic macular edema and other retinal disorders. American Journal of Ophthalmology. 2002;133(4):537–543.
    1. Adamis AP, Berman AJ. Immunological mechanisms in the pathogenesis of diabetic retinopathy. Seminars in Immunopathology. 2008;30(2):65–84.
    1. Sue Lane L, Jansen PD, Lahav M, Rudy C. Circulating prostacyclin and thromboxane levels in patients with diabetic retinopathy. Ophthalmology. 1982;89(7):763–766.
    1. Zhou J, Wang S, Xia X. Role of intravitreal inflammatory cytokines and angiogenic factors in proliferative diabetic retinopathy. Current Eye Research. 2012;37(5):416–420.
    1. Schoenberger SD, Kim SJ, Sheng J, Rezaei KA, Lalezary M, Cherney E. Increased prostaglandin E2 (PGE2) levels in proliferative diabetic retinopathy, and correlation with VEGF and inflammatory cytokines. Investigative Ophthalmology & Visual Science. 2012;53:5906–5911.
    1. Bressler SB, Qin H, Melia M, et al. Exploratory analysis of the effect of intravitreal ranibizumab or triamcinolone on worsening of diabetic retinopathy in a randomized clinical trial. JAMA Ophthalmology. 2013;131(8):1033–1040.
    1. Yanni SE, Barnett JM, Clark ML, Penn JS. The role of PGE2 receptor EP4 in pathologic ocular angiogenesis. Investigative Ophthalmology and Visual Science. 2009;50(11):5479–5486.
    1. Kern TS, Engerman RL. Pharmacological inhibition of diabetic retinopathy: aminoguanidine and aspirin. Diabetes. 2001;50(7):1636–1642.
    1. Effects of aspirin treatment on diabetic retinopathy. ETDRS report number 8. Early Treatment Diabetic Retinopathy Study Research Group. Ophthalmology. 1991;98:757–765.
    1. Powell EU, Field R. Diabetic retinopathy and rheumatoid arthritis. The Lancet. 1964;284(7349):17–18.
    1. Baudoin C, Passa P, Sharp P, Kohner E. Effect of aspirin alone and aspirin plus dipyridamole in early diabetic retinopathy. A multicenter randomized controlled clinical trial. Diabetes. 1989;38(4):491–498.
    1. Hattori Y, Hashizume K, Nakajima K, Nishimura Y, Naka M, Miyanaga K. The effect of long-term treatment with sulindac on the progression of diabetic retinopathy. Current Medical Research and Opinion. 2007;23(8):1913–1917.
    1. Chew EY, Kim J, Coleman HR, et al. Preliminary assessment of celecoxib and microdiode pulse laser treatment of diabetic macular edema. Retina. 2010;30(3):459–467.
    1. Callanan D, Williams P. Topical nepafenac in the treatment of diabetic macular edema. Clinical Ophthalmology. 2008;2:689–692.
    1. Soheilian M, Karimi S, Ramezani A, Peyman GA. Pilot study of intravitreal injection of diclofenac for treatment of macular edema of various etiologies. Retina. 2010;30(3):509–515.
    1. do Ceu Afonso Reis A, Vianna RNG, dos Reis RSM, Cardoso GP. Intravitreal injection of ketorolac tromethamine in patients with diabetic macular edema refractory to retinal photocoagulation. Arquivos Brasileiros de Oftalmologia. 2010;73(4):338–342.
    1. Maldonado RM, Vianna RNG, Cardoso GP, de Magalhães AV, Burnier MN., Jr. Intravitreal injection of commercially available ketorolac tromethamine in eyes with diabetic macular edema refractory to laser photocoagulation. Current Eye Research. 2011;36(8):768–773.
    1. Elbendary AM, Shahin MM. Intravitreal diclofenac versus intravitreal triamcinolone acetonide in the treatment of diabetic macular EDEMA. Retina. 2011;31(10):2058–2064.

Source: PubMed

Sponsor e collaboratori

Condizioni mediche

Interventi farmacologici

3
Sottoscrivi